Oncocyte : Investor Presentation

Oncocyte

Investor Presentation

NASDAQ: OCX

Josh Riggs

CEO

Q4 2023

Forward Looking Statement

Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include, among others, those pertaining to the Company's development and commercial model (including expected margin and cost, reimbursement, strategic partnerships, global scalability, capital efficiency, accelerated adoption and clinical development), anticipated timing of product development and launch and upcoming milestones, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte or its subsidiaries' financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

2

NASDAQ: OCX

NASDAQ: OCX

Oncocyte Investor Summary

3novel precision diagnostic tests for oncology and transplant, representing a

$10B+

clinical market opportunity1

• Differentiated, capital-light commercial model focused on profitability, not just revenue
• Competitive proprietary, patented technologies and published clinical data
• Potential disruption of mature diagnostic markets with strong existing reimbursement, limiting commercial risk
• CMS Coverage VitaGraft Kidney
• First RUO product launch targeted for 1H 2024
• Multiple additional value creating milestones expected over next four quarters

3

NASDAQ: OCX

1. Based on publicly available patient populations and anticipated reimbursement rates

Differentiated Strategy Focused on Profitability

Oncocyte Diagnostic Product Market Opportunity

Three novel diagnostic tests addressing large reimbursed markets

TransplantOncology

Is the transplanted organ		Will patient benefit from		Is the immunotherapy drug
damaged?		immunotherapy?		working?
$500M est. revenue currently		$1.5B est. revenue generated currently by		$200M est. revenue generated currently
generated by competitors		competing tests		by competing tests
$2B* est. US market		$2B** est. incremental US market		$4B** est. US market
$4B* est. worldwide		$4B** est. incremental worldwide market		$8B** est. worldwide
Well established path to reimbursement		Submitted for reimbursement in 4Q22
		Well established path to reimbursement
under blanket LCD				under blanket LCD

5	NASDAQ: OCX	• Competitor Estimate
		**Immunotherapy Drugs Market Size & Industry Growth | 2023 to 2028 (marketdataforecast.com)